Cardiovascular
Cardiovascular Disease
CROI 2015: Predicting Cardiovascular Disease in People with HIV -- Can We Do Better?
- Details
- Category: Cardiovascular Disease
- Published on Thursday, 09 April 2015 00:00
- Written by Theo Smart
Four existing models used to predict risk of cardiovascular disease (CVD) underestimated that risk in large cohorts of people living with HIV, according to research presented at the recent 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle. Other studies suggested that even without that underestimation being taken into account, many HIV-positive people are currently undertreated with statins, which could protect them from cardiovascular events like myocardial infarction.
CROI 2015: Statins May Reduce Risk of Heart Disease in People with HIV
- Details
- Category: Cardiovascular Disease
- Published on Friday, 06 March 2015 00:00
- Written by Theo Smart
Evidence is mounting that statin therapy can prevent the progression of coronary atherosclerosis (hardening and narrowing of the arteries supplying the heart) in people living with HIV, according to the results of 2 randomized clinical trials reported last week at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.
AIDS 2014: Weight Gain on ART May Raise Risk of Heart Disease and Diabetes
- Details
- Category: Cardiovascular Disease
- Published on Thursday, 24 July 2014 00:00
- Written by Liz Highleyman
People with HIV who gain weight shortly after starting antiretroviral therapy (ART) may have an increased risk of cardiovascular disease and diabetes, according to findings from the D:A:D study presented this week at the 20th International AIDS Conference in Melbourne, Australia.
Kaiser Study Shows No Elevated Heart Attack Risk for People with HIV
- Details
- Category: Cardiovascular Disease
- Published on Thursday, 29 January 2015 00:00
- Written by Liz Highleyman
A previously reported increase in the risk of myocardial infarction or heart attack among people living with HIV has been reversed in recent years, according to an analysis of nearly 25,000 Kaiser Permanent members published in the January 18 edition of Clinical Infectious Diseases. In 2010-2011, HIV positive patients were at no greater risk than HIV negative people.
Rilpivirine Is Associated with Less Blood Fat Elevation than Efavirenz
- Details
- Category: Cardiovascular Disease
- Published on Wednesday, 28 May 2014 00:00
- Written by Liz Highleyman
People with HIV who started first-line treatment with a regimen containing rilpivirine (Edurant, also in the Complera coformulation) had smaller blood lipid increases and were less likely to have abnormal levels than those who started on efavirenz (Sustiva, also in the Atripla coformulation), according to 2-year data from the ECHO and THRIVE trials published in the April 11 online edition of Clinical Infectious Diseases.
Web Design and Development by